Healthcare Professionals

Committed to helping you meet the evolving challenges and opportunities in patient care.

Healthcare Professionals
  • Critical Care

    Providing innovative therapies and technologies to help you treat patients with life-threatening illnesses in the Intensive Care Unit.

  • Hospital Care

    From the pharmacy to the bedside, we help you increase safety, streamline processes and build cost efficiency throughout the hospital.

  • Nutritional Care

    Acute and chronic nutritional care for your patients who are unable to get adequate nutrients orally or enterally.

  • Renal Care

    Pioneering innovation in haemodialysis and peritoneal dialysis to help you achieve better outcomes for your patients.

  • Surgical Care

    Delivering innovative surgical products that help you operate with confidence, precision and speed.

  • Our Products

    Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

Perspectives

For more than 85-years, we have worked at the intersection of saving and sustaining lives.

Perspectives
  • Patients' Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Healthcare Insights

    We’re engaging with industry thought leaders to explore how science and innovation advance healthcare.

  • Community Engagement

    Enriching the communities where we live and work.

  • People of Baxter

    Our organization is enriched by a diverse population of individuals that work together to drive better healthcare options for patients around the world.

Our Story

Our more than 85-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our Story
  • Our Commitment to Ireland

    Our presence in Ireland for more than 50 years

  • Our Governance

    We are proud of our strong commitment to maintaining the highest standards of corporate governance.

  • Fuelling Collaborative Innovation

    Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

  • Corporate Responsibility

    We are committed to doing business the right way, ensuring that we champion our employees, our communities, our customers and patients, and our environment in everything we do.

  • Inclusion & Diversity

    We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

Patients

Helping you reach a healthy life, full of possibility.

Patients
  • Critical Care

    When every moment counts, our therapies help healthcare professionals provide life-sustaining treatment to you or your loved ones.

  • Hospital Care

    From the pharmacy to the bedside, we support you and your healthcare providers with intravenous medications and infusion technologies designed with safety in mind.

  • Nutritional Care

    When medical conditions prevent you from adequately feeding yourself, we work with your healthcare provider to help you regain or maintain your health, through life-saving clinical nutrition options.

  • Renal Care

    Chronic kidney disease (CKD) is an ongoing journey. While every journey is unique, we are with you and your healthcare provider, every step of the way, providing options to meet your lifestyle needs.

  • Surgical Care

    We partner with surgical teams around the world so they can operate with confidence, precision and speed for a successful outcome to your surgery.

  • Empowering Patients

    We work in partnership with HSE organisations to enable you to self-care and manage your therapy at home.

Baxter Launches First 3-in-1 Set for use in Continuous Renal Replacement Therapy and Sepsis Management Protocols

Press Release

  • New indication for oXiris set to help remove excessive levels of cytokines and endotoxin in patients needing blood purification launched at ESICM

  • Elevated levels of inflammatory mediators cytokines and endotoxin are frequently seen in patients with sepsis, a serious medical condition affecting up to 40 percent of critically ill patients in the intensive care unit1-7

  • First approved use for oXiris outside of CRRT and fluid overload, adds to Baxter’s multi-organ therapy offering using the Prismaflex system

PDF

Newbury, UK -

Baxter Healthcare Ltd, a leader in acute care therapies, has announced a new indication for the company's oXiris set, which can now be used to help remove excessive levels of cytokines, endotoxin and other inflammatory mediators from a patient's blood. This makes oXiris the first blood purification set that can be used in continuous renal replacement therapy (CRRT) and sepsis management protocols. Baxter showcased the new indication at the recent European Society of Intensive Care Medicine (ESICM) congress in Vienna.

Previously, the oXiris set was only indicated for CRRT, which is a type of extracorporeal (outside the body) blood purification (EBP) used with Baxter’s Prismaflex system to manage patients with acute kidney injury (AKI).

The use of EBP to remove cytokines and endotoxin from the blood represents a promising approach to treat conditions where excessive levels of those inflammatory mediators are seen in the patient's blood.  For that reason, EBP is being studied for its potential to help address sepsis, a condition for which new therapeutic approaches have not shown to be effective.8 However, confirmation of such an association is challenging, in part due to the population of critically ill patients with AKI and/or sepsis, and because these patients often require multiple therapeutic interventions9 – a characteristic that complicates assessment of individual treatment outcomes.

"Extracorporeal blood purification for sepsis is an area where we do not have a lot of robust published research and where there is little scientific consensus, so it’s difficult for healthcare providers to determine the most effective way to treat their patients", said Thomas Rimmelé, M.D., PhD, chairman of the Anesthesia and Resuscitation Service Department at Hôpital Edouard Herriot in Lyon, France. "What I find most interesting about the oXiris set is that it is now able to filter the blood of cytokines and endotoxin while simultaneously treating acute kidney injury."

"Baxter is leading the way in advancing treatments for the most critically ill patients in a hospital and finding innovative solutions where there are few effective options available today," said Dr Mark Bechter, Medical Director UK, Ireland and Nordics at Baxter. "This launch illustrates our commitment to providing healthcare providers with new applications for products used on our leading Prismaflex system to drive better care."

Baxter received CE mark and regulatory approval for the label expansion in more than 30 countries in Europe and certain countries in the Middle East and Africa.

About Our Acute Therapies Portfolio

A leader in multi-organ support therapy options, Baxter has been at the forefront of advancing new technologies and revolutionising treatment for critically ill patients around the world. Baxter's leading Prismaflex system offers clinicians the flexibility to meet patients' diverse needs and powers our portfolio of products to deliver a complete range of extracorporeal (outside the body) blood purification (EBP) therapies to help manage patients with AKI, acute respiratory distress syndrome, autoimmune diseases and/or sepsis.

About Baxter

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-centre dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anaesthetics; and pharmacy automation, software and services. The company's global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter's employees worldwide are building upon the company's rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

This release includes forward-looking statements concerning Baxter and its oXiris set and its Prismaflex system, including oXiris' indications, use, effectiveness and risks and expectations with regard to its availability in countries in Europe, the Middle East, Africa, and other countries in the future. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply issues; patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

1 Pavon A, Binquet C, Kara F, et al. Profile of the risk of death after septic shock in the present era: an epidemiologic study. Crit Care Med. 2013;41:2600-2609.
2 Blanco J, Muriel-Bombin A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care. 2008;12:R158.
3 Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606-618.
4 Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004;30:589-596.
5 Karlsson S, Varpula M, Ruokonen E, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33:435-443.
6 Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308-1316.
7 Sjoding MW, Prescott HC, Wunsch H, Iwashyna TJ, Cooke CR. Longitudinal changes in ICU admissions among elderly patients in the United States. Crit Care Med. 2016;44:1353-1360.
8 Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45:486–552.
9 Hébert PC, et al. Chest 2002;121:1290 – 300.